Quantcast

Latest Biochemistry of Alzheimer's disease Stories

2008-08-29 18:00:12

By Lauran Neergaard WASHINGTON - Scientists for the first time have peered into people's brains to directly measure the ebb and flow of a substance notorious for its role in Alzheimer's disease. The delicate research was performed not with Alzheimer's patients but with people suffering severe brain injuries - because a brain injury increases the risk of developing dementia later in life. The goal is to learn why, so that doctors one day might be able to lower that risk. With this...

2008-08-29 09:00:14

By LAURAN NEERGAARD By Lauran Neergaard The Associated Press WASHINGTON Scientists for the first time have peered into people's brains to directly measure the ebb and flow of a substance notorious for its role in Alzheimer's disease. The delicate research was performed not with Alzheimer's patients but with people suffering severe brain injuries - because a brain injury increases the risk of developing dementia later in life. The goal is to learn why, so that doctors one day...

2008-08-08 09:00:28

ProteoTech has completed regulatory investigational new drug requirements and has received clearance from the FDA to initiate its Phase I human clinical trial on Exebryl-1, a small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. Initial studies suggest that Exebryl-1 may have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The...

2008-08-07 09:00:14

KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. ProteoTech initiated its Phase 1 human trial on July 29, 2008. At the 2008 International Conference on Alzheimer's...

2008-07-30 03:00:19

By John Fauber, Milwaukee Journal Sentinel Jul. 30--CHICAGO -- The first Alzheimer's drug that actually may arrest the progress of the disease showed promising results in early clinical trial research presented Tuesday in Chicago. The drug, which has been around since the 1930s and is used to treat urinary tract infections and also to make blue ink, allowed people with moderate Alzheimer's disease to remain stable for nearly two years while those who got a placebo continued to decline,...

2008-07-30 03:00:15

Researchers at Scotland's University of Aberdeen say a new drug they've developed holds great promise in slowing the progression of Alzheimer's disease. The test patients who took the medication had an 81 percent reduction in cognitive decline in one year, the researchers' Phase 2 clinical trial found. The university's Claude Wischik, working with TauRx Therapeutics of Singapore, developed the novel treatment based on a new approach that targets the tangles -- aggregates of abnormal...

2008-07-14 15:00:14

Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31. Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will...

2008-07-02 12:01:11

U.S. scientists say the protein neprilysin can reduce plaque formation and neuron death associated with Alzheimer's disease, but at the expense of lifespan. Thomas Jefferson University researchers said the buildup of amyloid-beta protein plaques within the brain is a hallmark of Alzheimer's. Normally, enzymes remove the plaques, and deficiencies in those enzymes are one potential disease cause. The scientists said neprilysin, or NEP, a major amyloid degrader, decreases naturally with age...

2008-06-24 00:01:08

By Randolph E. Schmid Associated Press WASHINGTON -- Researchers have uncovered a new clue to the cause of Alzheimer's disease. The brains of people with the memory-robbing form of dementia are cluttered with a plaque made up of beta-amyloid, a sticky protein. But there long has been a question whether this is a cause of the disease or a side effect. Also involved are tangles of a protein called tau; some scientists suspect this is the cause. Now, researchers have caused Alzheimer's...

a06110c303bfa7ee48817278c0417fd51
2008-06-23 15:03:52

Researchers from Harvard Medical School have made what they believe to be a key discovery in the cause of Alzheimer's disease. Their research found that people who suffer from a form of dementia that affects memory have a certain type of plaque in their brains. The plaque is made up of a sticky protein known as beta-amyloid.  Scientists have long questioned whether the presence of this plaque is an underlying cause, or merely a side effect, of the disease. Another protein, known as tau,...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related